Heart Disease & Cardiology Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches-Left Ventricular Dysfunction Trial

This Phase 3 trial is exploring different treatment methods for people with coronary artery disease who also have reduced heart function. It compares medical therapy and invasive procedures to see which approach better supports heart health and cognitive function. The study is enrolling patients in several countries, including the United States and Brazil, aiming to provide clearer guidance on the best treatment options for this condition.

Reperfusion Approach in Predicted In-hospital Delay for Primary PCI in STEMI

This Phase 4 trial is testing a new way to treat patients experiencing a specific type of heart attack called ST elevation myocardial infarction (STEMI) when there are delays in receiving the usual catheter-based treatment. The approach uses early clot-busting medication followed by catheterization, which could reduce heart damage by speeding up treatment. The study is recruiting patients in Russia and hopes to improve care for those facing treatment delays.

The Rule-Out Acute Myocardial Infarction Using Artificial Intelligence Electrocardiogram (ROMIAE) 2 Trial

This trial is investigating the use of artificial intelligence with ECG tests to quickly and accurately identify suspected heart attacks in emergency rooms. If successful, this method could help doctors rule out heart attacks faster, reducing unnecessary tests and hospital stays for patients with chest pain. The study is recruiting over 4,600 participants in South Korea, aiming to make emergency heart care more efficient.

Tirzepatide on Atrial Fibrillation Recurrence After Catheter Ablation in Patients With Obesity and HFpEF

This Phase 4 trial examines whether tirzepatide, a drug combined with lifestyle changes, can help reduce the return of atrial fibrillation, an irregular heart rhythm, after a procedure called catheter ablation. The study focuses on adults with obesity and a type of heart failure where the heart's pumping ability is preserved. Conducted in China with plans for 602 participants, the trial could offer a new way to improve long-term heart rhythm control and quality of life.

Colchicine's Effect on Inflammatory Markers

This Phase 4 study is testing colchicine, a medication, to see if it can reduce inflammation and prevent irregular heartbeats after heart bypass surgery. By lowering inflammation, colchicine might help reduce the risk of atrial fibrillation following surgery, potentially aiding recovery. The study is recruiting patients in the United States and involves taking capsules with follow-up blood tests to monitor effects.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.